News | December 16, 2010

Customized Solutions Meet the Demands of an Evolving Radiology Market

Customized Solutions Meet the Demands of an Evolving Radiology Market

December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting. The company is also showing regulatory progress related to its contrast media in computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, cardiac catheterization, interventional/diagnostic radiology and its contrast delivery systems.

“A number of factors are shaping the evolution of radiology today, including rapid innovation, cost control and an acute awareness of product safety,” said Carlo Medici, head of global commercial operations of Bracco Imaging and president and CEO, Bracco Diagnostics.

The company’s Isovue (iopamidol injection) is available in a convenient range of iodine concentrations and packaging options, making it the top osmolar contrast media agent in the United States.

The company also continues to see robust growth stemming from its 2008 acquisition of E-Z-EM, one of the most recognized brands among radiologists and gastrointestinal (GI) physicians. Among these are the company’s injector and data management systems, which enable radiologists, administrators and technologists to gain workflow efficiencies, imaging optimization and patient safety benefits. Also, through this acquisition, Bracco is now the only provider of barium-based oral imaging products.

Safety, Efficacy and Efficiency in MRI

The company’s gadolinium-based contrast agents (GBCAs) - MultiHance (gadobenate dimeglumine) and ProHance (gadoteridol) - are increasingly the MRI agents of choice by radiologists in more than 2,000 healthcare facilities in the United States.

MultiHance was the first and only contrast agent approved for MRI of the central nervous system (CNS) in the United States, with twice the relaxivity compared to other tested extracellular contrast agents. This means greater contrast-to-noise and lesion-to-brain ratio, which may lead to improved visualization. ProHance is the only macrocyclic gadolinium contrast agent available in the United States, with an exceptionally stable Gd chelate.

Nephrogenic systemic fibrosis (NSF), a rare and potentially life threatening syndrome in patients with renal impairment, has been associated with GBCAs. This has fueled significant clinical and scientific activity in attempts to determine the etiology of this disease. In response the U.S. Food and Drug Administration (FDA) recently published new guidelines defining specific classes of GBCAs based on risk of causing NSF. In a briefing document dated December 8, 2009, the FDA wrote: “Of the 5 GBCs considered, the higher risk is associated with Omniscan, Magnevist, and OptiMARK while the lowest risk is associated with ProHance and MultiHance.”

Further, the American College of Radiology that radiologists should administer GBCAs to renally impaired patients only where necessary. The ACR also advised using the lowest possible dose.

Studies demonstrate that MultiHance provides significantly greater diagnostic information and lesion visualization when compared to two other commonly used contrast agents used at an equivalent dose. It is also FDA-approved for intravenous use in MRI of the CNS in children over two years of age.

For more information: usa.braccoimaging.com

Related Content

The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...